New York, February 15, 2024 - PRISM MarketView - Atara Biotherapeutics (Nasdaq: ATRA) has submitted an Investigational New Drug (IND) application to the FDA for the use of ATA3219 as a monotherapy for the treatment of systemic lupus erythematosus
(SLE) with kidney involvement (lupus nephritis). Despite therapeutic advances, there remains a high unmet need for effective treatments for lupus nephritis.
(SLE) with kidney involvement (lupus nephritis). Despite therapeutic advances, there remains a high unmet need for effective treatments for lupus nephritis.
“We are dedicated to advancing medical breakthroughs with innovative cell therapies that truly make a difference. We look forward to working with the FDA to initiate this study and advance ATA3219 into the clinic to potentially bring a new disease-modifying option for patients suffering from this chronic disease.”
Rajani Dinavahi, Chief Medical Officer at Atara Biotherapeutics
Highlights
Atara’s ATA3219 IND submission includes robust in vitro data reflecting the CD19 antigen-specific functional activity of ATA3219 and CAR-mediated activity against B cells from SLE patients. ATA3219 led
to near-complete CD19-specific B-cell depletion compared to controls.
to near-complete CD19-specific B-cell depletion compared to controls.
ATA3219 combines the natural biology of unedited T cells with the benefits of an allogeneic therapy. Lupus nephritis is a serious and most common complication of SLE, a chronic multisystem autoimmune
disease. SLE affects around 200,000 people in the United States, and up to 60% of adult patients with SLE develop renal disease during the course of their illnes
disease. SLE affects around 200,000 people in the United States, and up to 60% of adult patients with SLE develop renal disease during the course of their illnes
About Atara Biotherapeutics, Inc.
Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients within
days. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile Epstein-
Barr virus (EBV) T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in
addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of hematological malignancies and B-cell driven autoimmune diseases. Atara is headquartered in Southern
California. For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn
days. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile Epstein-
Barr virus (EBV) T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in
addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of hematological malignancies and B-cell driven autoimmune diseases. Atara is headquartered in Southern
California. For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn
PRISM MarketView does not provide investment advice.
Media Contact
Company Name: Prism MarketView
Email: info@prismmarketview.com
Phone: 646-863-6341
Website: https://prismmarketview.com
Company Name: Prism MarketView
Email: info@prismmarketview.com
Phone: 646-863-6341
Website: https://prismmarketview.com
PRISM MarketView Social Media